Moderna (MRNA) Stock Looks Above Fair Value On Sales But Strong On Returns
Moderna stock has surged over the past year, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. This raises questions about how much of the good news is already reflected in the share price.
- Moderna has returned 472.5% over the past year, which puts recent optimism at the center of any discussion about what investors are now paying for future cash flows.
- The recent positive Phase 3 melanoma vaccine results can support higher long term growth expectations, while the key risk is that execution, regulatory decisions or follow up data do not ultimately translate that excitement into durable revenue and earnings.
- Moderna currently passes 0 of 6 valuation checks on Simply Wall St. This means the stock does not come across as a clear bargain on the broader metrics 0/6.
The issue now is whether Moderna's current price still leaves enough room for investors who are only considering the stock after this sharp move.
Is Moderna Getting Expensive on Sales?
P/S is often the go-to yardstick for Moderna because revenue is more established than earnings at this stage and the company is still investing heavily in its pipeline.
Moderna currently trades on a P/S of 26.0x, compared with around 13.1x for the broader biotech industry and about 8.9x for its peer group. Even after the recent Phase 3 melanoma vaccine success, that is a steep premium to what investors are paying for sales at many other biotechs.
The Simply Wall St model suggests a fair P/S closer to 4.5x, although the gap is widened by how heavily the model penalizes ongoing losses and risk around future cash flows. That figure is better read as a warning signal than a precise target, but it still points to Moderna screening as very expensive on sales, even after allowing for its oncology opportunity.
On the P/S multiple, Moderna stock currently screens as overvalued relative to both tailored and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Moderna Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Moderna valuation puzzle leaves off and spell out which future paths for revenue, margins and earnings would need to play out for Moderna stock to be worth materially more or less than today's price, as discussed on the Community page. Rather than focus on a single multiple or model output, each narrative lays out the key assumptions behind its view of fair value so you can compare them with actual results over time.
One of the top community narratives on Moderna: 228% overvalued
"Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high..."
Read one of the top narratives on Moderna
Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!
The Bottom Line
Moderna now screens as clearly overvalued on market multiples, with an extreme gap between its current P/S and both peers and the level suggested by broader checks. That premium leaves less room for disappointment if the melanoma vaccine and wider pipeline do not translate into the revenue and earnings profile implied by the price. For new money, the key question is whether Moderna can grow into this valuation through sustained commercial success, or whether expectations eventually settle closer to industry benchmarks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com